NO861241L - Fremgangsmaate for fremstilling av terapeutisk aktive dibenzo (be) oksepin-eddikksyrederivater. - Google Patents
Fremgangsmaate for fremstilling av terapeutisk aktive dibenzo (be) oksepin-eddikksyrederivater.Info
- Publication number
- NO861241L NO861241L NO861241A NO861241A NO861241L NO 861241 L NO861241 L NO 861241L NO 861241 A NO861241 A NO 861241A NO 861241 A NO861241 A NO 861241A NO 861241 L NO861241 L NO 861241L
- Authority
- NO
- Norway
- Prior art keywords
- general formula
- compound
- hydrogen atom
- alkyl group
- indicated above
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 10
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 150000001242 acetic acid derivatives Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 6
- 150000001768 cations Chemical class 0.000 claims abstract description 3
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 2
- 150000002148 esters Chemical class 0.000 claims description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000005698 Diels-Alder reaction Methods 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000011987 methylation Effects 0.000 claims description 3
- 238000007069 methylation reaction Methods 0.000 claims description 3
- 150000005690 diesters Chemical class 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 238000006356 dehydrogenation reaction Methods 0.000 claims 1
- 150000002920 oxepines Chemical class 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- -1 phenylsulphonyl group Chemical group 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 19
- 239000000203 mixture Substances 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000010992 reflux Methods 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- SDJHPPZKZZWAKF-UHFFFAOYSA-N 2,3-dimethylbuta-1,3-diene Chemical compound CC(=C)C(C)=C SDJHPPZKZZWAKF-UHFFFAOYSA-N 0.000 description 2
- XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- HYUPPKVFCGIMDB-UHFFFAOYSA-N ethyl 2-(4-hydroxyphenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(O)C=C1 HYUPPKVFCGIMDB-UHFFFAOYSA-N 0.000 description 2
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960001404 quinidine Drugs 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- LSFYCRUFNRBZNC-UHFFFAOYSA-N (2-hydroxyphenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1O LSFYCRUFNRBZNC-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 1
- MIMZGFBPGISKHQ-UHFFFAOYSA-N 2-(oxepin-3-yl)acetic acid Chemical compound OC(=O)CC1=COC=CC=C1 MIMZGFBPGISKHQ-UHFFFAOYSA-N 0.000 description 1
- FVMDYYGIDFPZAX-UHFFFAOYSA-N 3-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=CC(O)=C1 FVMDYYGIDFPZAX-UHFFFAOYSA-N 0.000 description 1
- ICBZSKCTKKUQSY-YUWZRIFDSA-N 4-[(1r,2s)-1-hydroxy-2-(methylamino)propyl]phenol;hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=C(O)C=C1 ICBZSKCTKKUQSY-YUWZRIFDSA-N 0.000 description 1
- DWRDZMRDJZOKLZ-UHFFFAOYSA-N 4-[3-(carboxymethyl)phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(CC(O)=O)=C1 DWRDZMRDJZOKLZ-UHFFFAOYSA-N 0.000 description 1
- FHBDJLIWTAVFDE-UHFFFAOYSA-N 4-[4-(carboxymethyl)phenoxy]butanoic acid Chemical compound OC(=O)CCCOC1=CC=C(CC(O)=O)C=C1 FHBDJLIWTAVFDE-UHFFFAOYSA-N 0.000 description 1
- WNXNUPJZWYOKMW-UHFFFAOYSA-N 5-bromopentanoic acid Chemical compound OC(=O)CCCCBr WNXNUPJZWYOKMW-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- XBPYCOFMLPRVMP-UHFFFAOYSA-N ethyl 4-[4-(2-ethoxy-2-oxoethyl)phenoxy]butanoate Chemical compound CCOC(=O)CCCOC1=CC=C(CC(=O)OCC)C=C1 XBPYCOFMLPRVMP-UHFFFAOYSA-N 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- SEFAOCNUWNPXHC-UHFFFAOYSA-N methyl 2-(5-oxo-2h-1-benzoxepin-7-yl)acetate Chemical compound O1CC=CC(=O)C2=CC(CC(=O)OC)=CC=C21 SEFAOCNUWNPXHC-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Reinforced Plastic Materials (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8505425A FR2580280B1 (fr) | 1985-04-11 | 1985-04-11 | Derives d'acide dibenzo(be)oxepinne-acetique, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO861241L true NO861241L (no) | 1986-10-13 |
Family
ID=9318116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO861241A NO861241L (no) | 1985-04-11 | 1986-03-26 | Fremgangsmaate for fremstilling av terapeutisk aktive dibenzo (be) oksepin-eddikksyrederivater. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4701466A (de) |
| EP (1) | EP0198762B1 (de) |
| JP (1) | JPS61236774A (de) |
| KR (1) | KR860008159A (de) |
| AT (1) | ATE38225T1 (de) |
| AU (1) | AU577687B2 (de) |
| CA (1) | CA1243326A (de) |
| DE (1) | DE3661011D1 (de) |
| DK (1) | DK161186A (de) |
| ES (1) | ES8704475A1 (de) |
| FI (1) | FI861527A (de) |
| FR (1) | FR2580280B1 (de) |
| GR (1) | GR860949B (de) |
| HU (1) | HU196388B (de) |
| IL (1) | IL78358A (de) |
| NO (1) | NO861241L (de) |
| NZ (1) | NZ215781A (de) |
| PT (1) | PT82365B (de) |
| ZA (1) | ZA862709B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2608606B1 (fr) * | 1986-12-22 | 1989-03-10 | Synthelabo | Derives d'acide dibenzo(be)oxepinne-acetique, leur preparation et leur application en therapeutique |
| US5175286A (en) * | 1988-09-20 | 1992-12-29 | Hisamitsu Pharmaceutical Co., Inc. | Dibenz[b,e]oxepin derivatives |
| DE3919255A1 (de) * | 1989-06-13 | 1990-12-20 | Bayer Ag | Dibenzo/1,5/dioxocin-5-one-derivate, ihre verwendung in arzneimitteln und verfahren zu ihrer herstellung |
| TWI410420B (zh) | 2008-02-05 | 2013-10-01 | Dainippon Sumitomo Pharma Co | 苄基哌啶化合物 |
| CN103113342B (zh) * | 2013-02-05 | 2014-07-02 | 浙江大学 | 一种苯骈七元杂环类化合物及其制备方法和应用 |
| CN103554077B (zh) * | 2013-10-29 | 2014-12-17 | 云南烟草科学研究院 | 一种色酮类化合物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4585788A (en) * | 1973-09-06 | 1986-04-29 | American Hoechst Corporation | 6,11-dihydrodibenz[b,e]oxepin-acetic acids and derivatives |
| US4107322A (en) * | 1976-06-03 | 1978-08-15 | American Hoechst Corporation | Benzyl and related esters of 6,11-dihydrodibenz[b,e]oxepin-acetic acids |
| JPS56156273A (en) * | 1980-03-31 | 1981-12-02 | Dainippon Pharmaceut Co Ltd | Acetic derivative |
| AU543037B2 (en) * | 1981-07-13 | 1985-03-28 | Merck & Co., Inc. | Dibenz (b,e) oxepin compounds |
-
1985
- 1985-04-11 FR FR8505425A patent/FR2580280B1/fr not_active Expired
-
1986
- 1986-03-26 NO NO861241A patent/NO861241L/no unknown
- 1986-03-31 IL IL78358A patent/IL78358A/xx unknown
- 1986-04-02 AT AT86400709T patent/ATE38225T1/de not_active IP Right Cessation
- 1986-04-02 DE DE8686400709T patent/DE3661011D1/de not_active Expired
- 1986-04-02 EP EP86400709A patent/EP0198762B1/de not_active Expired
- 1986-04-10 NZ NZ215781A patent/NZ215781A/xx unknown
- 1986-04-10 US US06/851,114 patent/US4701466A/en not_active Expired - Fee Related
- 1986-04-10 ZA ZA862709A patent/ZA862709B/xx unknown
- 1986-04-10 ES ES553855A patent/ES8704475A1/es not_active Expired
- 1986-04-10 HU HU861514A patent/HU196388B/hu unknown
- 1986-04-10 GR GR860949A patent/GR860949B/el unknown
- 1986-04-10 KR KR1019860002715A patent/KR860008159A/ko not_active Application Discontinuation
- 1986-04-10 DK DK161186A patent/DK161186A/da not_active IP Right Cessation
- 1986-04-10 JP JP61084032A patent/JPS61236774A/ja active Pending
- 1986-04-10 FI FI861527A patent/FI861527A/fi not_active Application Discontinuation
- 1986-04-10 AU AU55916/86A patent/AU577687B2/en not_active Ceased
- 1986-04-10 CA CA000506332A patent/CA1243326A/en not_active Expired
- 1986-04-10 PT PT82365A patent/PT82365B/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT82365B (fr) | 1988-03-18 |
| CA1243326A (en) | 1988-10-18 |
| AU577687B2 (en) | 1988-09-29 |
| AU5591686A (en) | 1987-10-15 |
| FR2580280A1 (fr) | 1986-10-17 |
| ES8704475A1 (es) | 1987-04-01 |
| IL78358A0 (en) | 1986-07-31 |
| DK161186D0 (da) | 1986-04-10 |
| EP0198762A1 (de) | 1986-10-22 |
| HUT40637A (en) | 1987-01-28 |
| FI861527A0 (fi) | 1986-04-10 |
| ATE38225T1 (de) | 1988-11-15 |
| KR860008159A (ko) | 1986-11-12 |
| HU196388B (en) | 1988-11-28 |
| US4701466A (en) | 1987-10-20 |
| DE3661011D1 (en) | 1988-12-01 |
| FI861527A (fi) | 1986-10-12 |
| FR2580280B1 (fr) | 1987-05-22 |
| EP0198762B1 (de) | 1988-10-26 |
| NZ215781A (en) | 1988-08-30 |
| ZA862709B (en) | 1986-11-26 |
| GR860949B (en) | 1986-08-06 |
| IL78358A (en) | 1990-09-17 |
| JPS61236774A (ja) | 1986-10-22 |
| ES553855A0 (es) | 1987-04-01 |
| PT82365A (fr) | 1986-05-01 |
| DK161186A (da) | 1986-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68929049T2 (de) | 1,4-Diazepin-Derivate und deren pharmazeutische Verwendung | |
| US3420851A (en) | Novel dibenzoxepines | |
| US4124713A (en) | Oxopyridobenzoxepin-acetic acids and derivatives thereof useful as antiinflammatory and analgesic agents | |
| EP0091241A2 (de) | Kondensierte Pyrrolinon-Derivate, und ihre Herstellung | |
| NO834637L (no) | Fremgangsmaate ved fremstilling av nye tieno(2,3-6)-pyrrolderivater | |
| NO861241L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive dibenzo (be) oksepin-eddikksyrederivater. | |
| US4670462A (en) | Substituted 1,3,4,9-tetrahydropyrano(3,4-B)indole-1-acetic acids | |
| JPH06211829A (ja) | トリエン側鎖を有する新規クロメン化合物 | |
| CN100402534C (zh) | 一种三环类化合物及其在制药中的应用 | |
| US4659728A (en) | Hydroxy substituted 4,5-diphenyl-2-oxazole propanoic acid | |
| US4740518A (en) | 4H-benzo(4,5)cyclohepta(1,2-B)thiophene derivatives | |
| US3663627A (en) | 1-indanmethanols | |
| US3892774A (en) | Cyclo pentathiophene derivatives | |
| Wasserman et al. | Studies on the Mucohalic Acids. II. The Synthesis of Fused α-Lactam-thiazolidines Related to Penicillin1 | |
| US3086972A (en) | Aza-thiaxanthene derivatives | |
| JPS6332786B2 (de) | ||
| Ackrell et al. | New heterocyclic systems. Benzo [4, 5] cyclohepta [1, 2‐b] pyrrole and benzo [5, 6] cyclohepta [1, 2‐f] pyrrolizidine derivatives | |
| US3865843A (en) | 4-Oxo-4H-benzo{8 4.5{9 cyclohepta{8 1,2-b{9 thiophene derivatives | |
| CA1276158C (en) | 4h-benzo[4,5]cyclohepta[1,2-b]thiophene derivatives | |
| US4906757A (en) | Process for the preparation of dextrorotatory 3-(3-pyridyl)-1H,3H-pyrrolo [1,2-c]-7-thiazolecarboxylic acid | |
| US3678058A (en) | 1,3,4,9B-TETRAHYDRO-2(2H)-INDENO-{8 1,2-c{9 PYRIDINES | |
| US3442903A (en) | Certain aminopropylidenebenzo(5,6)cyclohepta(1,2-d)thiazoles | |
| US3291800A (en) | 3-substituted derivatives of yohimbane alkaloids and process for their production | |
| US4709048A (en) | Production of substituted 2,3,4,9-tetrahydro-1H-carbazole-1-acetic acid derivatives | |
| US4855445A (en) | Substituted-8-alkenyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids |